A Study to Evaluate the Safety and Effectiveness of SPR001 in Adults with Classic Congenital Adrenal Hyperplasia

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effect of Tildacerfont in reducing androstenedione (hormone, A4) in subjects with Classic Adrenal Hyperplasia (CAH) over approximately 86 weeks.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Male and female subjects over 18 years old, inclusive

- Has a known childhood diagnosis of classic CAH due to 21-hydroxylase deficiency based
on genetic mutation in CYP21A2 and/or documented elevated 17-OHP and currently treated
with HC, HC acetate, prednisone, prednisolone, methylprednisolone (or a combination of
the aforementioned GCs)

- Has been on a stable supraphsiologic dose of GC replacement ≥15 mg/day and ≤60 mg/day
in HC equivalents

- For subjects with the salt-wasting form of CAH, subject has been on a stable dose of
mineralocorticoid replacement for ≥1 month before screening

Exclusion Criteria:

- Has a known or suspected diagnosis of any other known form of classic CAH (not due to
21 hydroxylase deficiency)

- Has a history that includes bilateral adrenalectomy or hypopituitarism

- Has a history of allergy or hypersensitivity to Tildacerfont, any of its excipients,
or any other CRF1 receptor antagonist

- Current treatment with dexamethasone as GC therapy for CAH. Prior treatment with
dexamethasone is allowed as long as the transition to an alternative GC regimen (eg,
HC, prednisone, or prednisolone) has resulted in a stable dose of GC replacement for
≥1 month before screening.

- Shows clinical signs or symptoms of adrenal insufficiency

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 1/16/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Irina Bancos, M.D., M.S.

Cerrado para la inscripción

Contact information:

Vanessa Fell M.A.

(507) 266-6068

Fell.Vanessa@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20507812

Mayo Clinic Footer